Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Technology Inc.

Division of Boston Scientific Corp.

Latest From Heart Technology Inc.

The J&J Lesson

J&J's exit from the coronary angioplasty market was a sign of the end of an era. Without a product at the high end of innovation, it was left with a basic product that in the interim had become commoditized.

Medical Device

Depression Bolsters the Neuromodulation Market

More than a decade ago, venture capitalists identified neurostimulation as a fertile new field for investment, but efforts to date have produced more disappointments than results. The losing streak appears to be over: the FDA recently cleared Neuronetics to begin selling its NeuroStar TMS system for treatment-resistant depression. Meanwhile, Northstar Neuroscience has received FDA approval for the second study of its Renova cortical stimulation device for treating major depressive disorder.
Medical Device

David Auth: Riding Heart Technology's Roller Coaster

Heart Technology is one of the great success stories in medical devices over the past 20 years. But you'd never have predicted that given the company's early experiences. In Vivo interviews the company's founder, David Auth.
Medical Device Business Strategies

Atherectomy Devices: At the Cutting Edge of Peripheral Vascular Disease

In the past, many medical device companies have seen PVD as a smaller offshoot of the coronary market and have sought to tap the opportunity primarily as a kind of commercial and technological second thought. Thus, they've largely tried to adapt devices developed for the coronary vasculature to peripheral applications-stents are the best example-only to fail, not because the market for PVD devices isn't there, but because significant differences between the anatomy of the peripheral and coronary vasculature mean that coronary devices don't always translate well to this new area. Now, though, as suggested by the success of FoxHollow, which recently went public, one of the most product areas for PVD may be a technology that has been around for a long time in coronary therapy but has gained a shaky reputation: atherectomy. New companies with interventional plaque clearing technologies-Cardiovascular Systems, Pathway Medical, and Minnow Medical-are thus targeting PVD first, coronary arteries, second.
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • David Auth, PhD, Chmn. & CEO
    William Scott, VP, Fin. & CFO
    Alan Levy, PhD, Pres. & COO
    Karl Mosch, SVP, Sales & Mktg.
  • Contact Info
  • Heart Technology Inc.
    Phone: (206) 869-6160
    17425 N.E. Union Hill Rd.
    Redmond, WA 98052-3376
    USA
UsernamePublicRestriction

Register